---
title: "Intra-Cellular Therap (ITCI.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ITCI.US.md"
symbol: "ITCI.US"
name: "Intra-Cellular Therap"
industry: "制药"
---

# Intra-Cellular Therap (ITCI.US)

| Item | Detail |
|------|--------|
| Industry | 制药 |

## Company Profile

Intra-Cellular Therapies, Inc.是一家生物制药公司，专注于小分子药物的发现、临床开发和商业化，主要针对美国的精神和神经疾病的医疗需求。该公司提供 CAPLYTA，用于治疗成人的精神分裂症和双相抑郁症。它还参与开发 lumateperone，目前正在进行针对重度抑郁症的第三阶段临床试验，以及针对儿童患者的精神分裂症、双相障碍和与自闭症谱系障碍相关的易怒症。此外，该公司还在进行第二阶段临床试验的 lenrispodun（ITI-214），用于治疗帕金森病；ITI-1284-ODT-SL 在第二阶段试验中用于治疗广泛性焦虑障碍，以及阿尔茨海默病患者的精神病和激动；ITI-...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:14.000Z

**Overall: B (0.34)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 35 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 46.62% |  |
| Net Profit YoY | 46.54% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 680.85M |  |


**Multi Score**: B

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -8.58% | D |
| Profit Margin | -10.97% | D |
| Gross Margin | 56.95% | B |

#### Growth Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 46.62% | A |
| Net Profit YoY | 46.54% | B |
| Total Assets YoY | 87.69% | A |
| Net Assets YoY | 94.19% | A |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -911.74% | E |
| OCF YoY | 46.62% | A |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.65 | B |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 15.98% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Intra-Cellular Therap",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-8.58%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-10.97%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "56.95%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "A",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "46.62%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "46.54%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "87.69%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "94.19%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-911.74%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "46.62%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.65",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "15.98%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 礼来 (US.LLY) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 03 | 罗氏(ADR) (US.RHHBY) | A | B | B | D | C | B |
| 04 | 阿斯利康 (US.AZN) | A | B | C | D | C | B |
| 05 | 诺华制药 (US.NVS) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -187.76 | 236/257 | - | - | - |
| PB | 12.21 | 181/257 | 12.21 | 12.21 | 12.21 |
| PS (TTM) | 20.59 | 145/257 | 20.59 | 20.59 | 20.59 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 131.87 |

## References

- [Company Overview](https://longbridge.com/en/quote/ITCI.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ITCI.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ITCI.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.